Physician profile
Deana Buan
NPI 1427010784
$5,571.83
in general payments reported to CMS, 2019-2025
29 companies · $989 in 2025
The $989 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,081 · 2022: $1,377 · 2023: $1,066 · 2024: $1,058 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,113.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,746.06 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $1,275.89 | 2021-2025 | |
| Evofem Biosciences, INC. | $537.71 | 2021-2025 | Solosec, Phexx, Phexxi |
| Sumitomo Pharma America, INC. | $319.91 | 2023-2024 | Myfembree |
| Myovant Sciences INC. | $230.90 | 2021-2022 | |
| Exact Sciences Corporation | $146.53 | 2023-2024 | Cologuard Collection Kit |
| Galderma Laboratories, L.P. | $125.01 | 2021 | |
| Lundbeck LLC | $124.99 | 2024 | Vyepti |
| Aspira Women'S Health INC | $118.63 | 2022-2024 | Ova1 |
| Inspire Medical Systems, INC. | $109.42 | 2024 | Inspire |
| Millicent US INC | $86.85 | 2024-2025 | Femring, Intrarosa, Femlyv |
| Organon LLC | $82.71 | 2021-2024 | |
| Hologic Sales and Service, LLC | $74.64 | 2024-2025 | Aptima |
| Pfizer INC. | $62.08 | 2021-2023 | |
| Exeltis, USA INC. | $61.77 | 2022-2023 | Slynd |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $61.32 | 2021-2024 | Bd Max System, Bd Max Instrument, Bd Onclarity |
| Avion Pharmaceuticals | $61.30 | 2021-2022 | |
| Coopersurgical, INC. | $61.15 | 2022-2023 | Paragard T 380a |
| Daiichi Sankyo INC. | $44.80 | 2022 | |
| Impel Pharmaceuticals INC. | $41.86 | 2023 | Trudhesa |
| Therapeuticsmd, INC. | $35.34 | 2021-2022 | |
| Mycovia Pharmaceuticals, INC. | $29.85 | 2022-2023 | Vivjoa |
| Roche Diagnostics Corporation | $23.03 | 2021 | |
| Agile Therapeutics, INC. | $22.19 | 2021 | |
| Astellas Pharma US INC | $20.11 | 2024 | Veozah |
| Acella Pharmaceuticals, LLC | $18.12 | 2023 | NP Thyroid 60 |
| Merck Sharp & Dohme LLC | $18.08 | 2021 | |
| Olympus America INC. | $16.46 | 2022 | |
| Ascend Therapeutics US, LLC | $15.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deana Buan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.